Department of Medicine and Research Institute for Internal Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
J Hepatol. 2010 May;52(5):712-7. doi: 10.1016/j.jhep.2009.11.029. Epub 2010 Mar 4.
BACKGROUND & AIMS: The HLA complex on chromosome 6p21 is firmly established as a risk locus for primary sclerosing cholangitis (PSC). We aimed to exploit genetic differences between Northern Europe and Italy in an attempt to define a causative locus in this genetic region.
Seventy-eight North-Italian PSC patients and 79 controls were included. We performed sequencing-based genotyping of HLA-C, HLA-B, and HLA-DRB1. The major histocompatibility chain-related A (MICA) transmembrane microsatellite was analysed using PCR fragment length determination. The tumour necrosis factor-alpha (TNF-alpha)-308G-->A polymorphism was genotyped with TaqMan. Allele frequencies were compared with Chi-square tests. Uncorrected p-values <0.05 were considered statistically significant when replicating findings in previous studies. The p-values of novel associations were corrected for multiple comparisons (Bonferroni).
The frequency of the strong inhibitory HLA-C2 killer-immunoglobulin receptor (KIR) ligand variant was significantly reduced in PSC vs. controls (0.39 vs. 0.58, p=0.0006). Consequently, HLA-C1 homozygosity was associated with an increased risk of PSC (OR 3.1; 95% CI 1.4-6.7, p=0.004). Importantly, there were no significant associations with the HLA-Bw4 KIR ligand variant, at the neighbouring MICA locus or with TNF-alpha-308G-->A. At HLA-DRB1, we confirmed positive and negative associations with DRB115 and DRB107, respectively, while there were no associations with the DRB1*03, *04 or *1301 alleles typically detected in PSC in Northern Europe.
The strong inhibitory of the KIR ligand HLA-C2 protects against PSC development in all populations hitherto studied. Further studies on the role of natural killer cells and T-lymphocytes expressing KIRs in PSC pathogenesis are warranted.
染色体 6p21 上的 HLA 复合体被确定为原发性硬化性胆管炎(PSC)的风险基因座。我们旨在利用北欧和意大利之间的遗传差异,试图在该遗传区域中确定一个致病基因座。
纳入 78 名意大利北部 PSC 患者和 79 名对照。我们对 HLA-C、HLA-B 和 HLA-DRB1 进行基于测序的基因分型。采用 PCR 片段长度测定法分析主要组织相容性链相关 A(MICA)跨膜微卫星。采用 TaqMan 方法对肿瘤坏死因子-α(TNF-α)-308G-->A 多态性进行基因分型。采用卡方检验比较等位基因频率。当复制以前研究中的发现时,未校正的 p 值<0.05 被认为具有统计学意义。对新发现的关联进行了多重比较(Bonferroni)校正。
与对照组相比,PSC 患者中强抑制性 HLA-C2 杀伤免疫球蛋白受体(KIR)配体的频率显著降低(0.39 对 0.58,p=0.0006)。因此,HLA-C1 纯合与 PSC 风险增加相关(OR 3.1;95% CI 1.4-6.7,p=0.004)。重要的是,在邻近的 MICA 基因座或 TNF-α-308G-->A 处,与 HLA-Bw4 KIR 配体变体均无显著相关性。在 HLA-DRB1 中,我们证实了与 DRB115 和 DRB107 的阳性和阴性关联,而与通常在北欧检测到的 PSC 中的 DRB1*03、04 或1301 等位基因无关联。
KIR 配体 HLA-C2 的强抑制作用可预防所有已研究人群的 PSC 发生。进一步研究 NK 细胞和表达 KIR 的 T 淋巴细胞在 PSC 发病机制中的作用是必要的。